Publications by authors named "I Sanjose"
Seed germination and seedling establishment are very sensitive plant stages to metal pollution. Many halophyte species colonizing salt marshes are able to germinate and establish in highly contaminated habitats and low marsh halophyte species seem to show higher tolerance to metals than high marsh species. We analyzed the effects of copper, zinc and nickel in concentrations up to 2000 μM on seed germination and seedling growth in two closely related species of Sarcocornia, S.
View Article and Find Full Text PDFSeed germination and seedling establishment are the stages most sensitive to abiotic stress in the plant life cycle. We analyzed the effects of copper, zinc and nickel on seed germination and early seedling growth of native Spartina maritima and invasive S. densiflora from polluted and non-polluted estuaries.
View Article and Find Full Text PDFBackground: To facilitate population screening and clinical trials of disease-modifying therapies for Alzheimer's disease, supportive biomarker information is necessary. This study was aimed to investigate the association of plasma amyloid-beta (Aβ) levels with the presence of pathological accumulation of Aβ in the brain measured by amyloid-PET. Both plasma Aβ42/40 ratio alone or combined with an FDG-PET-based biomarker of neurodegeneration were assessed as potential AD biomarkers.
View Article and Find Full Text PDFBackground: Easily accessible biomarkers are needed for the early identification of individuals at risk of developing Alzheimer's disease (AD) in large population screening strategies.
Objectives: This study evaluated the potential of plasma β-amyloid (Aβ) biomarkers in identifying early stages of AD and predicting cognitive decline over the following two years.
Design: Total plasma Aβ42/40 ratio (TP42/40) was determined in 83 cognitively normal individuals (CN) and 145 subjects with amnestic mild cognitive impairment (a-MCI) stratified by an FDG-PET AD-risk pattern.
Article Synopsis
- A new active vaccine, ABvac40, targeting the amyloid-β peptide was developed for Alzheimer's disease and tested in a phase I clinical trial for safety and tolerability.
- The trial involved 24 patients with mild to moderate AD, who were randomly assigned to receive either the vaccine or a placebo, with a focus on documenting any adverse effects and measuring immune response.
- Initial results showed that both groups experienced similar rates of adverse events, suggesting that the vaccine was generally safe and tolerated, but no significant differences were found in the occurrence of specific imaging abnormalities related to amyloid treatment.